Income Statement of the Merck Group

XLS

€ million

Q2 – 2011

Q2 – 2010

Jan.–June
2011

Jan.–June
2010

Sales

2,469.6

2,102.8

4,947.1

4,125.6

Royalty, license and commission income

85.8

105.2

172.0

181.3

Total revenues

2,555.4

2,208.0

5,119.1

4,306.9

 

 

 

 

 

Cost of sales

–760.4

–517.2

–1,400.0

–1,003.9

Gross margin

1,795.0

1,690.8

3,719.1

3,303.0

 

 

 

 

 

Marketing and selling expenses

–605.1

–540.2

–1,196.6

–1,008.4

Royalty, license and commission expenses

–118.5

–117.3

–229.8

–239.5

Administration expenses

–126.4

–115.2

–251.3

–219.6

Other operating expenses and income

–270.4

–109.4

–367.5

–244.4

Research and development

–369.1

–338.8

–748.6

–686.0

Amortization of intangible assets

–319.0

–145.9

–567.2

–286.4

Investment result

2.0

2.2

2.1

2.2

Operating result

–11.4

326.2

360.1

621.0

 

 

 

 

 

Exceptional items

–11.1

–1.2

146.9

–1.2

Earnings before interest and tax (EBIT)

–22.5

325.0

507.0

619.8

 

 

 

 

 

Financial result

–74.6

–78.3

–142.8

–116.9

Profit before tax

–97.0

246.8

364.2

502.9

 

 

 

 

 

Income tax

12.9

–59.9

–104.1

–121.4

Profit after tax

–84.0

186.9

260.1

381.5

 

 

 

 

 

Non-controlling interest

–1.9

–3.5

–5.0

–6.6

Net profit after non-controlling interest

–85.9

183.4

255.2

374.8

 

 

 

 

 

Earnings per share (in €)

 

 

 

 

basic

–0.40

0.84

1.17

1.72

diluted

–0.40

0.84

1.17

1.72